# PWDs on SGLT2 inhibitors have 2x risk of amputation and DKA

**URL:** https://forum.fudiabetes.org/t/pwds-on-sglt2-inhibitors-have-2x-risk-of-amputation-and-dka/5526
**Category:** T1 Research
**Created:** [November 17, 2018, 11:42am UTC](https://forum.fudiabetes.org/t/pwds-on-sglt2-inhibitors-have-2x-risk-of-amputation-and-dka/5526 "2018-11-17T11:42:08Z")
**Posts on this page:** 1
**Page:** 1

<div class="post-metadata">

### Author: ![Michel](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.fudiabetes.org/michel/32/387_2.png) [@Michel](https://forum.fudiabetes.org/u/Michel)
#### Post date: [November 17, 2018, 11:42am UTC](https://forum.fudiabetes.org/t/pwds-on-sglt2-inhibitors-have-2x-risk-of-amputation-and-dka/5526/1 "2018-11-17T11:42:08Z")

</div>

This is a new, large observational study, which muddies up the field of SGLT2 inhibitors. It links use of SGLT2 inhibitors in general with a 2x risk of lower limb amputation and of Diabetic Keto Acidosis.

So far, one SGLT2 invibitor (invokana/Invokamet, or canagliflozin) had been linked with higher amputation risk, but the others (dapagliflozin and empagliflozin) were not.

In this study, only 1% of SGLT2 patients were taking canagliflozin: the other 99% were taking dapagliflozin or empagliflozin.

Here is a discussion of the study on WebMD:

> **[Some Diabetes Drugs, Higher Amputation Risk Linked](https://www.webmd.com/diabetes/news/20181115/some-diabetes-drugs-higher-amputation-risk-linked)**
>
> People on sodium-glucose cotransporter2 (SGLT2) inhibitors were twice as likely to require a lower limb amputation as people taking another type of diabetes medication, Scandinavian researchers have found.

It is important to note that this is an observational study only: it finds links between use of SGLT2 inhibitors and amputation/DKA, but it cannot prove a causal relationship between the two.

The study attempted to account for a number of factors before reporting the link.